Pages that link to "Q412197"
Jump to navigation
Jump to search
The following pages link to irinotecan (Q412197):
Displayed 50 items.
- leukemia (Q29496) (← links)
- World Health Organization Model List of Essential Medicines (Q37155) (← links)
- breast cancer (Q128581) (← links)
- colorectal cancer (Q188874) (← links)
- stomach cancer (Q189588) (← links)
- lymphoma (Q208414) (← links)
- pancreatic cancer (Q212961) (← links)
- FOLFIRI (Q1389369) (← links)
- rectum cancer (Q2739660) (← links)
- non-small-cell lung carcinoma (Q3658562) (← links)
- alveolar rhabdomyosarcoma (Q4737958) (← links)
- idelalisib (Q5908266) (← links)
- IFL chemotherapy regimen (Q5970794) (← links)
- XELIRI (Q8041833) (← links)
- brain cancer (Q9303627) (← links)
- FOLFIRINOX (Q17144959) (← links)
- rectum adenocarcinoma (Q18554959) (← links)
- colon cancer (Q18555025) (← links)
- colon adenocarcinoma (Q18555055) (← links)
- colonic benign neoplasm (Q18555061) (← links)
- germ cell cancer (Q18555254) (← links)
- pancreatic adenocarcinoma (Q18556189) (← links)
- Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial (Q21260391) (← links)
- BRAF V600E (Q21851559) (← links)
- Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression-free survival in patients with advanced and/or metastatic colorectal cancer (Q24186145) (← links)
- Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for advanced and/or metastatic colorectal cancer (Q24200737) (← links)
- Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for advanced and/or metastatic colorectal cancer (Q24234555) (← links)
- Advanced small cell carcinoma of the uterine cervix treated by neoadjuvant chemotherapy with irinotecan and cisplatin followed by radical surgery (Q24627204) (← links)
- UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer (Q24648015) (← links)
- Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics (Q24651239) (← links)
- Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer (Q24795149) (← links)
- Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer (Q24795784) (← links)
- Health hazard evaluation report: evaluation of chemotherapy drug exposure in an outpatient infusion center (Q24977607) (← links)
- FOLFOXIRI (Q25326960) (← links)
- Nanomedicine developments in the treatment of metastatic pancreatic cancer: focus on nanoliposomal irinotecan (Q26751368) (← links)
- Comparison of first-line chemotherapy based on irinotecan or other drugs to treat non-small cell lung cancer in stage IIIB/IV: a systematic review and meta-analysis (Q26775554) (← links)
- Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer (Q26775949) (← links)
- Fifteen years of irinotecan therapy for pediatric sarcoma: where to next? (Q26795742) (← links)
- Topoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapy (Q27851526) (← links)
- UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy (Q27851574) (← links)
- Assessment of the topoisomerase I gene copy number as a predictive biomarker of objective response to irinotecan in metastatic colorectal cancer (Q27852685) (← links)
- Schlafen-11 sensitizes colorectal carcinoma cells to irinotecan (Q27853056) (← links)
- Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer. (Q27853084) (← links)
- Favorable response to trastuzumab plus irinotecan combination therapy in two patients with HER2-positive relapsed small-cell lung cancer (Q27853123) (← links)
- Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer (Q27860681) (← links)
- Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial (Q28036747) (← links)
- Irinotecan treatment in cancer patients with UGT1A1 polymorphisms (Q28178430) (← links)
- Pharmacogenomics of human UDP-glucuronosyltransferases and irinotecan toxicity (Q28218156) (← links)
- Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan (Q28249001) (← links)
- Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy (Q28265991) (← links)